Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer

Reproductive Biology and Endocrinology

Volumn 2, Issue , 2004, Pages

  Stewart, Delisha A ^a   Cooper, Carlton R ^a   Sikes, Robert A ^a  

^a UNIVERSITY OF DELAWARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FIBRONECTIN; GELATINASE A; GELATINASE B; GROWTH FACTOR; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; MATRIX METALLOPROTEINASE 14; NERVE CELL ADHESION MOLECULE; OSTEOCALCIN; OSTEONECTIN; OSTEOPONTIN; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR 1; SCLEROPROTEIN; SIALOPROTEIN; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UROKINASE RECEPTOR; UVOMORULIN; VITRONECTIN; TUMOR PROTEIN;

BONE METASTASIS; CANCER CELL; CANCER GROWTH; CANCER INVASION; EXTRACELLULAR MATRIX; HUMAN; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; METASTASIS; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HUMANS; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS;

EID: 4344713411     PISSN: 14777827     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-7827-2-2     Document Type: Review

References (164)

1. Parkin DM, Pisani P, Ferlay J: Global Cancer Statistics. CA Cancer Journal Clinicians 1999, 49:33-64.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 2003, 53:5-26.
3. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ: Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 2000, 6:1038-1045.
4. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000, 31:578-583.
5. Jacobs SC: Spread of prostatic cancer to bone. Urology 1983, 21:337-344.
6. Koutsilieris M: Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol Hematol 1995, 18:51-64.
7. Rubens RD: Bone metastases-the clinical problem. Eur J Cancer 1998, 34:210-213.
8. Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, Blute ML: Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 2002, 95:1028-1036.
9. Radinsky R, Fidler IJ: Regulation of tumor cell growth at organ-specific metastases. In Vivo 1992, 6:325-331.
10. Mundy GR: Mechanisms of bone metastasis. Cancer 1997, 80:1546-1556.
11. Cooper CR,, Chay CH, Gendernalik JD, Lee H-L, Bhatia J, Taichman RS, McCauley LK, Keller ET, Pienta KJ: Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 2003, 97:739-747.
12. Gopalkrishnan RV, Kang DC, Fisher PB: Molecular markers and determinants of prostate cancer metastasis. J Cell Physiol 2001, 189:245-256.
13. Ellis LM, Fidler IJ: Angiogenesis and metastasis. Eur J Cancer 1996, 32A:2451-2460.
14. Cooper CR, Pienta KJ: Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer Prostatic Dis 2000, 3:6-12.
15. Lehr Jeffrey E., Pienta Kenneth J.: Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. Journal of the National Cancer Institute 1998, 90:118-123.
16. Chay Christopher H., Cooper Carlton R., Hellerstedt Beth A., Pienta Kenneth J.: Antimetastatic drugs in prostate cancer. Clinical Prostate Can 2002, 1:14-19.
17. Batson OV: The vertebral system of veins as a means for cancer dissemination. Prog Clin Cancer 1967, 3:1-18.
18. Batson OV: The function of the vertebral veins and their role in the spread of metastases. Clin Orthop 1995, 1940:4-9.
19. Holly SP, Larson MK, Parise LV: Multiple roles of integrins in cell motility. Exp Cell Res 2000, 261:69-74.
20. Hornebeck W, Emonard H, Monboisse JC, Bellon G: Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin Cancer Biol 2002, 12:231-241.
21. Condeelis JS, Wyckoff JB, Bailly M, Pestell R, Lawrence D, Backer J, Segall JE: Lamellipodia in invasion. Semin Cancer Biol 2001, 11:119-128.
22. Cooper CR, Bhatia JK, Muenchen HJ, McLean L, Hayasaka S, Taylor J, Poncza PJ, Pienta KJ: The regulation of prostate cancer cell adhesion to human bone marrow endothelial cell monolayers by androgen dihydrotestosterone and cytokines. Clin Exp Metastasis 2002, 19:25-33.
23. Okegawa T, Li Y, Pong RC, Hsieh JT: Cell adhesion proteins as tumor suppressors. J Urol 2002, 167:1836-1843.
24. Chay Christopher H., Cooper Carlton R., Gendernalik James D., Dhanasekaran Saravana M., Chinnaiyan Arul M., Rubin Mark, Schmaier Alvin H., Pienta Kenneth J.: A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 2002, 60:760-765.
25. Chung LW, Kao C, Sikes RA, Zhau HE: Human prostate cancer progression models and therapeutic intervention. Hinyokika Kiyo 1997, 43:815-820.
26. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW: Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994, 57:406-412.
27. Thalmann George N., Anezinis Ploutarchos E., Chang Shi-Ming, Zhau Haiyen E., Kim E. Edmund, Hopwood Vicki L., Pathak Sen, Eschenbach Andrew C. von, Chung Leland W. K.: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994, 54:2577-2581.
28. Hyytinen ER, Thalmann GN, Zhau HE, Karhu R, Kallioniemi OP, Chung LW, Visakorpi T: Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. Br J Cancer 1997, 75:190-195.
29. Kiefer JA, Farach-Carson MC: Type I collagen-mediated proliferation of PC3 prostate carcinoma cell line: implications for enhanced growth in the bone microenvironment. Matrix Biol 2001, 20:429-437.
30. Zhau HY, Zhou J, Symmans WF, Chen BQ, Chang SM, Sikes RA, Chung LW: Transfected neu oncogene induces human prostate cancer metastasis. Prostate 1996, 28:73-83.
31. Vafa A, Zhang Y, Sikes RA, Marengo SR: Overexpression of p185erbB2/neu in the NbE prostatic epithelial cell line increases cellular spreading and the expression of integrin alpha6beta1. Int J Oncol 1998, 13:1191-1197.
32. Koeneman KS, Yeung F, Chung LW: Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999, 39:246-261.
33. Lin CC, Lu YP, Lou YR, Ho CT, Newmark HH, MacDonald C, Singletary KW, Huang MT: Inhibition by dietary dibenzoylmethane of mammary gland proliferation, formation of DMBA-DNA adducts in mammary glands, and mammary tumorigenesis in Sencar mice. Cancer Lett 2001, 168:125-132.
34. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW: Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999, 5:2271-2277.
35. Chung LW, Zhau HE, Wu TT: Development of human prostate cancer models for chemoprevention and experimental therapeutics studies. J Cell Biochem Suppl 1997, 29:174-181.
36. Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewe W, de Leval J, Castronovo V: Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 1998, 90:1000-1008.
37. Bussemakers MJ, Van Bokhoven A, Tomita K, Jansen CF, Schalken JA: Complex cadherin expression in human prostate cancer cells. Int J Cancer 2000, 85:446-450.
38. Nagle RB, Hao J, Knox JD, Dalkin BL, Clark V, Cress AE: Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. Am J Pathol 1995, 146:1498-1507.
39. Xue Y, Li J, Latijnhouwers MA, Smedts F, Umbas R, Aalders TW, Debruyne FM, De La Rosette JJ, Schalken JA: Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia and prostate carcinoma. Br J Urol 1998, 81:844-851.
40. Brar PK, Dalkin BL, Weyer C, Sallam K, Virtanen I, Nagle RB: Laminin alpha-1, alpha-3, and alpha-5 chain expression in human prepubertal [correction of prepubetal] benign prostate glands and adult benign and malignant prostate glands. Prostate 2003, 55:65-70.
41. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991, 251:1451-1455.
42. Kemler R: From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 1993, 9:317-321.
43. Behrens J: Cadherins as determinants of tissue morphology and suppressors of invasion. Acta Anat 1994, 149:165-169.
44. Behrens J: Cell contacts, differentiation, and invasiveness of epithelial cells. Invasion Metastasis 1994, 14:61-70.
45. Birchmeier W, Behrens J: Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994, 1198:11-26.
46. Takeichi M: Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993, 5:806-811.
47. Umbas R, Schalken JA, Aalders TW, al. et: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992, 52:5104-5109.
48. Murant SJ, Rolley N, Phillips SM, Stower M, Maitland NJ: Allelic imbalance within the E-cadherin gene is an infrequent event in prostate carcinogenesis. Genes Chromosomes Cancer 2000, 27:104-109.
49. Tran NL, Nagle RB, Cress AE, Heimark RL: N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with Stromal cells. Am J Pathol 1999, 155:787-798.
50. Day ML, Zhao X, Vallorosi CJ, Putzi M, Powell CT, Lin C, Day KC: E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. J Biol Chem 1999, 274:9656-9664.
51. Hazan RB, Kang L, Whooley BP, Borgen PI: N-cadherin promotes adhesion between invasive breast cancer cells and the stroma. Cell Adhes Commun 1997, 4:399-411.
52. Hagios C, Lochter A, Bissell MJ: Tissue architecture: the ultimate regulator of epithelial function? Phil Trans R Soc London Series B: Biol Sci 1998, 353:857.
53. Okazaki M, Takeshita S, Kawai S, Kikuno R, Tsujimura A, Kudo A, Amann E: Molecular cloning and characterization of OB-cadherin, a new member of cadherin family expressed in osteoblasts. J Biol Chem 1994, 269:12092-12098.
54. Pauli Bendicht U., Lee Cho-Lea: Organ preference of metastasis: The role of organ-specifically modulated endothelial cells. Laboratory Investigation 1988, 58:379-387.
55. Augustin-Voss HG, Johnson RC, Pauli BU: Modulation of endothelial cell surface glycoconjugate expression by organ-derived biomatrices. Exp Cell Res 1991, 192:346-351.
56. Haraldsen G, Kvale D, Lien B, Farstad IN, Brandtzaeg P: Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. Journal of Immunology 1996, 156:2558-2565.
57. Kostenuik PJ, Singh G, Orr FW: Transforming growth factor beta upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen. Clin Exp Metastasis 1997, 15:41-52.
58. Khatib AM, Kontogiannea M, Fallavollita L, Jamison B, Meterissian S, Brodt P: Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Res 1999, 59:1356-1361.
59. Varner JA, Cheresh DA: Tumor angiogenesis and the role of vascular cell integrin alphav beta3. Important Advances in Oncology (Edited by:VT DeVita, S Hellman and SA Rosenberg). Philadelphia, Lippincott-Raven Publishers 1996, 66-87.
60. Albelda SM: Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993, 68:4-17.
61. Aplin AE, Howe A, Alahari SK, Juliano RL: Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 1998, 50:197-263.
62. Schwartz MA, Schaller MD, Ginsberg MH: Integrins: emerging paradigms of signal transduction. Annu Rev Cell Dev Biol 1995, 11:549-599.
63. Edlund Magnus, Miyamoto Tadayuki, Sikes Robert A., Ogle Roy, Laurie Gordon W., Farach-Carson Mary C., Otey Carol A., Zhau Haiyen E., Chung Leland W. K.: Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ 2001, 12:99-107.
64. Hemler ME, Elices MJ, Chan BM, Zetter B, Matsuura N, Takada Y: Multiple ligand binding functions for VLA-2 (alpha 2 beta 1) and VLA-3 (alpha 3 beta 1) in the integrin family. Cell Differ Dev 1990, 32:229-238.
65. Rokhlin OW, Cohen MB: Expression of cellular adhesion molecules on human prostate tumor cell lines. Prostate 1995, 26:205-212.
66. Schmelz M, Cress AE, Scott KM, Burger F, Cui H, Sallam K, McDaniel KM, Dalkin BL, Nagle RB: Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites. Neoplasia 2002, 4:243-254.
67. Cooper Carlton R., McLean Lisa, Mucci Neil R., Poncza Paul, Pienta Kenneth J.: Prostate cancer cell adhesion to quiescent endothelial cells is not mediated by beta-1 integrin subunit. Anticancer Research 2000, 20:4159-4162.
68. Prifti S, Zourab Y, Koumouridis A, Bohlmann M, Strowitzki T, Rabe T: Role of integrins in invasion of endometrial cancer cell lines. Gynecol Oncol 2002, 84:12-20.
69. Eliceiri BP, Cheresh DA: Role of alpha v integrins during angiogenesis. Cancer J 2000, 6 Suppl 3:S245-9.
70. Cooper CR, Chay CH, Pienta KJ: The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 2002, 4:191-194.
71. Seiffert D: Detection of vitronectin in mineralized bone matrix. J Histochem Cytochem 1996, 44:275-280.
72. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM: The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995, 95:713-724.
73. Hullinger TG, McCauley LK, Dejoode ML, Somerman MJ: Effect of bone proteins on human prostate cancer cell lines in vitro. Prostate 1998, 36:14-22.
74. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR: Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 1999, 59:1655-1664.
75. Byzova Tatiana V., Kim Wes, Midura Ronald J., Plow Edward F.: Activation of integrin avB3 regulates cell adhesion and migration on bone sialoprotein. Exp Cell Res 2000, 254:299-308.
76. Zheng Duo-Qi, Woodard Amy S., Tallini Giovanni, Languino Lucia R.: Substrate specificity of avb3 integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. Journal of Biological Chemistry 2000, 275:24565-24574.
77. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, Margue C, Cohen-Solal M, Buffet A, Kieffer N, Clezardin P: Integrin alpha (v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB 2002, 16:1266-1268.
78. Mercurio AM, Rabinovitz I: Towards a mechanistic understanding of tumor invasion - lessons from the alpha6beta 4 integrin. Semin Cancer Biol 2001, 11:129-141.
79. Rabinovitz I, Nagle RB, Cress AE: Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Clin Exp Metastasis 1995, 13:481-491.
80. Bonkhoff H, Stein U, Remberger K: Differential expression of alpha 6 and alpha 2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: simultaneous demonstration of cell surface receptors and their extracellular ligands. Hum Pathol 1993, 24:243-248.
81. Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, Dalkin BL, Nagle RB: Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. Am J Pathol 1994, 145:167-174.
82. Rabinovitz I, Mercurio AM: The integrin alpha6beta4 functions in carcinoma cell migration on laminin-1 by mediating the formation and stabilization of actin- containing motility structures. J Cell Biol 1997, 139:1873-1884.
83. Kitazawa S, Maeda S: Development of skeletal metastases. Clin Orthop 1995, 45-50.
84. von Bredow DC, Nagle RB, Bowden GT, Cress AE: Cleavage of beta4 Integrin by Matrilysin. Experimental Cell Res 1997, 236:341-345.
85. Dans M, Gagnoux-Palacios L, Blaikie P, Klein S, Mariotti A, Giancotti FG: Tyrosine phosphorylation of the beta 4 integrin cytoplasmic domain mediates Shc signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes. J Biol Chem 2001, 276:1494-1502.
86. Cress AE, Rabinovitz I, Zhu W, Nagle RB: The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev 1995, 14:219-228.
87. Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ: Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 1997, 33:263-271.
88. Bonaccorsi L, Muratori M, Carloni V, Zecchi S, Formigli L, Forti G, Baldi E: Androgen receptor and prostate cancer invasion. Int J Androl 2003, 26:21-25.
89. Aprikian AG, Tremblay L, Han K, Chevalier S: Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins. Int J Cancer 1997, 72:498-504.
90. Miyake H, Nelson C, Rennie PS, Gleave ME: Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 2000, 141:2257-2265.
91. Lin J, Adam RM, Santiestevan E, Freeman MR: The phosphatidylinositol 3′-kinase pathway is a dominant growth factor- activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999, 59:2891-2897.
92. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ: Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001, 142:4795-4805.
93. Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, Wang PH, Chen YT, Chang C: Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun 2003, 305:462-469.
94. Beresford SA, Davies MA, Gallick GE, Donato NJ: Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells. J Interferon Cytokine Res 2001, 21:313-322.
95. Downward J: Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998, 10:262-267.
96. Sonoda Yoshiko, Watanbe Shiro, Matsumoto Yaeko, Aizu-Yokota Eriko, Kasahara Tadashi: FAK is the upstream signal protein of the phosphatidylinositol 3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line. Journal of Biological Chemistry 1999, 274:10566-10570.
97. Kostenuik PJ, Sanchez-Sweatman O, Orr FW, Singh G: Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Clin Exp Metastasis 1996, 14:19-26.
98. Festuccia C, Bologna M, Gravina GL, Guerra F, Angelucci A, Villanova I, Millimaggi D, Teti A: Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int J Cancer 1999, 81:395-403.
99. Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000, 10:415-433.
100. Rigg AS, Lemoine NR: Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Ther 2001, 8:869-878.
101. Del Rosso M, Fibbi G, Pucci M, D'Alessio S, Del Rosso A, Magnelli L, Chiarugi V: Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin Exp Metastasis 2002, 19:193-207.
102. Nemeth JA, Harb JF, Barroso U., Jr., He Z, Grignon DJ, Cher ML: Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999, 59:1987-1993.
103. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, Cher ML: Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002, 94:17-25.
104. Lichtinghagen R, Musholt PB, Lein M, Romer A, Rudolph B, Kristiansen G, Hauptmann S, Schnorr D, Loening SA, Jung K: Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol 2002, 42:398-406.
105. Nagakawa O, Murakami K, Yamaura T, Fujiuchi Y, Murata J, Fuse H, Saiki I: Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 2000, 155:173-179.
106. Usmani BA, Shen R, Janeczko M, Papandreou CN, Lee WH, Nelson WG, Nelson JB, Nanus DM: Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res 2000, 6:1664-1670.
107. Li Z, Hou WS, Bromme D: Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. Biochemistry 2000, 39:529-536.
108. Bonnefoy A, Legrand C: Proteolysis of subendothelial adhesive glycoproteins (fibronectin, thrombospondin, and von Willebrand factor) by plasmin, leukocyte cathepsin G, and elastase. Thromb Res 2000, 98:323-332.
109. Ioachim E, Kamina S, Kontostolis M, Agnantis NJ: Immunohistochemical expression of cathepsin D in correlation with extracellular matrix component, steroid receptor status and proliferative indices in breast cancer. Virchows Arch 1997, 431:311-316.
110. Fernandez PL, Farre X, Nadal A, Fernandez E, Peiro N, Sloane BF, Shi GP, Chapman HA, Campo E, Cardesa A: Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer 2001, 95:51-55.
111. Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL, Sloane BF, Gleason DF: Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer. Prostate 2001, 48:274-284.
112. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E: Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 2003, 18:222-230.
113. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW: LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 2000, 44:91-103 Jul 1;44(2)..
114. Miles LA, Dahlberg CM, Plescia J, al. et: Role of cell-surface lysines in plasminogen binding to cells: Identification of alpha enolase as a candidate plasminogen receptor.
115. Andreasen PA, Egelund R, Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000, 57:25-40.
116. Hoosein NM, Boyd DD, Hollas WJ, Mazar A, Henkin J, Chung LW: Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun 1991, 3:255-264.
117. Xing RH, Rabbani SA: Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo. Endocrinology 1999, 140:4056-4064.
118. Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A, Bologna M: Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 1998, 16:513-528.
119. Chapman HA: Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997, 9:714-724.
120. Chapman HA, Wei Y, Simon DI, Waltz DA: Role of urokinase receptor and caveolin in regulation of integrin signaling. Thromb Haemost 1999, 82:291-297.
121. Ossowski L, Aguirre-Ghiso JA: Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000, 12:613-620.
122. Mainiero F, Pepe A, Yeon M, Ren Y, Giancotti FG: The intracellular functions of alpha6beta4 integrin are regulated by EGF. J Cell Biol 1996, 134:241-253.
123. Ridley AJ, Hall A: The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992, 70:389-399.
124. Nagle RB, Knox JD, Wolf C, Bowden GT, Cress AE: Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem Suppl 1994, 19:232-237.
125. Dedhar S, Saulnier R, Nagle R, Overall CM: Specific alterations in the expression of alpha 3 beta 1 and alpha 6 beta 4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane. Clin Exp Metastasis 1993, 11:391-400.
126. Witkowski Colette M., Rabinovitz Isaac, Nagle Raymmond B., Affinito Kit-Sahn D., Cress Anne E.: Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines. J Cancer Res Clin Oncol 1993, 119:637-644.
127. Hughes PE, Pfaff M: Integrin affinity modulation. Trends Cell Biol 1998, 8:359-364.
128. Elices MJ, Hemler ME: The human integrin VLA-2 is a collagen receptor on some cells and a collagen/laminin receptor on others. Proc Natl Acad Sci U S A 1989, 86:9906-9910.
129. O'Toole TE, Mandelman D, Forsyth J, Shattil SJ, Plow EF, Ginsberg MH: Modulation of the affinity of integrin alpha IIb beta 3 (GPIIb-IIIa) by the cytoplasmic domain of alpha IIb. Science 1991, 254:845-847.
130. Sims PJ, Ginsberg MH, Plow EF, Shattil SJ: Effect of platelet activation on the conformation of the plasma membrane glycoprotein IIb-IIIa complex. J Biol Chem 1991, 266:7345-7352.
131. Clark EA, Brugge JS: Integrins and signal transduction pathways: the road taken. Science 1995, 268:233-239.
132. Burridge K, Chrzanowska-Wodnicka M: Focal adhesions, contractility, and signaling. Annu Rev Cell Dev Biol 1996, 12:463-518.
133. Schoenwaelder SM, Burridge K: Bidirectional signaling between the cytoskeleton and integrins. Curr Opin Cell Biol 1999, 11:274-286.
134. Chung LW, Davies R: Prostate epithelial differentiation is dictated by its surrounding stroma. Mol Biol Rep 1996, 23:13-19.
135. Giancotti FG, Ruoslahti E: Integrin signaling. Science 1999, 285:1028-1032.
136. DiPersio CM, Hodivala-Dilke KM, Jaenisch R, Kreidberg JA, Hynes RO: alpha3beta1 Integrin is required for normal development of the epidermal basement membrane. J Cell Biol 1997, 137:729-742.
137. Rabinovitz I, Cress AE, Nagle RB: Biosynthesis and secretion of laminin and S-laminin by human prostate carcinoma cell lines. Prostate 1994, 25:97-107.
138. Calof AL, Campanero MR, O'Rear JJ, Yurchenco PD, Lander AD: Domain-specific activation of neuronal migration and neurite outgrowth-promoting activities of laminin. Neuron 1994, 13:117-130.
139. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V: Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997, 277:225-228.
140. Cooper Carlton R., Sikes Robert A., Nicholson Brian E., Sun Yan-Xi, Pienta Kenneth J., Taichman Russell S.: Cancer cells homing to bone: the significance of chemotaxis and cell adhesion. The biology of skeletal metastases (Edited by: Evan Keller and Leland WChung). Kluwer Academic Publishers-in press 2003.
141. Liapis H, Adler LM, Wick MR, Rader JS: Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol 1997, 28:443-449.
142. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA: Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 1996, 98:426-433.
143. Elgavish A, Prince C, Chang PL, Lloyd K, Lindsey R, Reed R: Osteopontin stimulates a subpopulation of quiescent human prostate epithelial cells with high proliferative potential to divide in vitro. Prostate 1998, 35:83-94.
144. Marengo SR, Sikes RA, Anezinis P, Chang SM, Chung LW: Metastasis induced by overexpression of p185neu-T after orthotopic injection into a prostatic epithelial cell line (NbE). Mol Carcinog 1997, 19:165-175.
145. Sikes RA, Chung LW: Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene. Cancer Res 1992, 52:3174-3181.
146. Chung LW, Chang SM, Bell C, Zhau H, Ro JY, von Eschenbach AC: Prostatic carcinogenesis evoked by cellular interaction. Environ Health Perspect 1988, 77:23-28.
147. Chung LW, Chang SM, Bell C, Zhau HE, Ro JY, von Eschenbach AC: Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals. Int J Cancer 1989, 43:1179-1187.
148. Bae VL, Jackson-Cook CK, Brothman AR, Maygarden SJ, Ware JL: Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. Int J Cancer 1994, 58:721-729.
149. Bae VL, Jackson-Cook CK, Maygarden SJ, Plymate SR, Chen J, Ware JL: Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 1998, 34:275-282.
150. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU 145). International Journal of Cancer 1978, 21:274-281.
151. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA: The LNCaP cell line-a new model for studies on human prostatic carcinoma. Progress in Clinical & Biological Research 1980, 37:115-132.
152. Korenchuk S, Lehr JE, L M. Clean, Lee YG, Whitney S, Vessella R, Lin DL, Pienta KJ: VCaP, a cell-based model system of human prostate cancer. In Vivo 2001, 15:163-168.
153. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investigative Urology 1979, 17:16-23.
154. Rios-Doria Jonathan, Day Kathleen C., Kuefer Rainer, Rashid Michael G., Chinnaiyan Arul M., Rubin Mark A., Day Mark L.: The Role of Calpain in the Proteolytic Cleavage of E-cadherin in Prostate and Mammary Epithelial Cells. The Journal Of Biological Chemistry 2003, 278:1372-1379.
155. Usmani BA, Harden B, Maitland NJ, Turner AJ: Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines. Clin Sci (Lond) 2002, 103 Suppl 48:314S-317S..
156. Conover CA, Perry JE, Tindall DJ: Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J Clin Endocrinol Metab 1995, 80:987-993.
157. Nunn SE, Peehl DM, Cohen P: Acid-activated insulin-like growth factor binding protein protease activity of cathepsin D in normal and malignant prostatic epithelial cells and seminal plasma. J Cell Physiol 1997, 171:196-204.
158. Manes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, Mira E, Martinez AC: The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cell. J Biol Chem 1999, 274:6935-6945.
159. Waltregny D, Bellahcene A, de Leval X, Florkin B, Weidle U, Castronovo V: Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 2000, 15:834-843.
160. Ylikoski A, Pettersson K, Nurmi J, Irjala K, Karp M, Lilja H, Lovgren T, Nurmi M: Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease. Clin Chem 2002, 48:1265-1271.
161. Kanoh Y, Akahoshi T, Ohara T, Ohtani N, Mashiko T, Ohtani S, Egawa S, Baba S: Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res 2002, 22:1813-1817.
162. Hashimoto K, Kihira Y, Matuo Y, Usui T: Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J Urol 1998, 160:1872-1876.
163. Chambon M, Rebillard X, Rochefort H, Brouillet JP, Baldet P, Guiter J, Maudelonde T: Cathepsin D cytosolic assay and immunohistochemical quantification in human prostate tumors. Prostate 1994, 24:320-325.
164. Uria JA, Lopez-Otin C: Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res 2000, 60:4745-4751.